136 related articles for article (PubMed ID: 17600978)
1. Incidence of chemotherapy-related tumour lysis syndrome at Kenyatta National Hospital, Nairobi.
Busakhala W; Joshi MD; Abinya NO; Amayo A; Abwao HO
East Afr Med J; 2007 Mar; 84(3):100-9. PubMed ID: 17600978
[TBL] [Abstract][Full Text] [Related]
2. The clinical management of tumour lysis syndrome in haematological malignancies.
Will A; Tholouli E
Br J Haematol; 2011 Jul; 154(1):3-13. PubMed ID: 21554259
[TBL] [Abstract][Full Text] [Related]
3. Tumour Lysis Syndrome in children with haematological cancers: Experience at a tertiary care hospital in Karachi.
Saeed F; Ali MS; Ashraf MS; Vadsaria K; Siddiqui DE
J Pak Med Assoc; 2018 Nov; 68(11):1625-1630. PubMed ID: 30410139
[TBL] [Abstract][Full Text] [Related]
4. Delays in diagnosis, referral and management of head and neck cancer presenting at Kenyatta National Hospital, Nairobi.
Onyango JF; Macharia IM
East Afr Med J; 2006 Apr; 83(4):85-91. PubMed ID: 16863003
[TBL] [Abstract][Full Text] [Related]
5. Testicular cancer at Kenyatta National Hospital, Nairobi.
Opot EN; Magoha GA
East Afr Med J; 2000 Feb; 77(2):80-5. PubMed ID: 10774080
[TBL] [Abstract][Full Text] [Related]
6. Oncological emergencies: tumor lysis syndrome.
Sobota J; Püsküllüoglu M; Zygulska AL
Przegl Lek; 2014; 71(4):210-4. PubMed ID: 25141580
[TBL] [Abstract][Full Text] [Related]
7. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
Cheuk DK; Chiang AK; Chan GC; Ha SY
Cochrane Database Syst Rev; 2014 Aug; (8):CD006945. PubMed ID: 25121561
[TBL] [Abstract][Full Text] [Related]
8. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
Darmon M; Vincent F; Camous L; Canet E; Bonmati C; Braun T; Caillot D; Cornillon J; Dimicoli S; Etienne A; Galicier L; Garnier A; Girault S; Hunault-Berger M; Marolleau JP; Moreau P; Raffoux E; Recher C; Thiebaud A; Thieblemont C; Azoulay E;
Br J Haematol; 2013 Aug; 162(4):489-97. PubMed ID: 23772757
[TBL] [Abstract][Full Text] [Related]
9. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model.
Montesinos P; Lorenzo I; Martín G; Sanz J; Pérez-Sirvent ML; Martínez D; Ortí G; Algarra L; Martínez J; Moscardó F; de la Rubia J; Jarque I; Sanz G; Sanz MA
Haematologica; 2008 Jan; 93(1):67-74. PubMed ID: 18166787
[TBL] [Abstract][Full Text] [Related]
10. Tumor lysis syndrome in children with non-Hodgkin lymphoma.
Alavi S; Arzanian MT; Abbasian MR; Ashena Z
Pediatr Hematol Oncol; 2006; 23(1):65-70. PubMed ID: 16326415
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of Single-dose Rasburicase in Patients With Lymphoid Malignancies at a High Risk for Tumor Lysis Syndrome.
Jeon YW; Kwak DH; Park SS; Yoon JH; Lee SE; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Min WS; Cho SG
Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):595-603. PubMed ID: 28711571
[TBL] [Abstract][Full Text] [Related]
12. A predictive model for the detection of tumor lysis syndrome during AML induction therapy.
Mato AR; Riccio BE; Qin L; Heitjan DF; Carroll M; Loren A; Porter DL; Perl A; Stadtmauer E; Tsai D; Gewirtz A; Luger SM
Leuk Lymphoma; 2006 May; 47(5):877-83. PubMed ID: 16753873
[TBL] [Abstract][Full Text] [Related]
13. Impact of daytime continuous veno-venous haemofiltration on treatment of paediatric tumour lysis syndrome.
Wang Y; Lu J; Tao Y
J Int Med Res; 2018 Sep; 46(9):3613-3620. PubMed ID: 29882457
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
Feng X; Dong K; Pham D; Pence S; Inciardi J; Bhutada NS
J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846
[TBL] [Abstract][Full Text] [Related]
15. Incidence and pathogenesis of tumor lysis syndrome.
Locatelli F; Rossi F
Contrib Nephrol; 2005; 147():61-68. PubMed ID: 15604606
[TBL] [Abstract][Full Text] [Related]
16. Tumour lysis syndrome: new therapeutic strategies and classification.
Cairo MS; Bishop M
Br J Haematol; 2004 Oct; 127(1):3-11. PubMed ID: 15384972
[TBL] [Abstract][Full Text] [Related]
17. High Risk of Tumor Lysis Syndrome in Symptomatic Patients with Multiple Myeloma with Renal Dysfunction Treated with Bortezomib.
Oiwa K; Morita M; Kishi S; Okura M; Tasaki T; Matsuda Y; Tai K; Hosono N; Ueda T; Yamauchi T
Anticancer Res; 2016 Dec; 36(12):6655-6662. PubMed ID: 27919998
[TBL] [Abstract][Full Text] [Related]
18. Appendicitis at Kenyatta National Hospital, Nairobi.
Chavda SK; Hassan S; Magoha GA
East Afr Med J; 2005 Oct; 82(10):526-30. PubMed ID: 16450681
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.
Cairo MS; Coiffier B; Reiter A; Younes A;
Br J Haematol; 2010 May; 149(4):578-86. PubMed ID: 20331465
[TBL] [Abstract][Full Text] [Related]
20. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase.
Wössmann W; Schrappe M; Meyer U; Zimmermann M; Reiter A
Ann Hematol; 2003 Mar; 82(3):160-5. PubMed ID: 12634948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
